Regeneron Pharmaceuticals
Biopharma giant behind Eylea, Dupixent, and Libtayo, with a genomics-driven drug pipeline.
On the record
Checkpoint: Sandoz and Celltrion both expected to launch Eylea biosimilars, plus Fianlimab lead-plaintiff deadline
The call
Regeneron's cash, Dupixent growth, and genetics data keep it standing, while Eylea biosimilars and a failed melanoma trial squeeze its near-term numbers and reputation.
Regeneron makes prescription medicines, including Eylea for eye disease, which brought in about $6 billion a year. Competitors like Amgen and Sandoz are now selling cheaper copycat versions of Eylea, which will eat into Regeneron's sales and profits starting now and through 2026. The company has enough cash and other drug candidates in development to survive this pressure, but investors betting on strong returns may be disappointed if Eylea sales drop faster than new drugs like Dupixent or obesity treatments can make up the difference.
Why
01
AI pressure: None apparent. No AI product is taking patients or revenue; AI is a tool Regeneron uses internally for drug discovery, not a predator here. Could AI do the core job? Unlikely.
02
Bigger players: Amgen (Pavblu), Sandoz (Enzeevu), Celltrion, Biocon Biologics (Yesafili), Samsung Bioepis (Opuviz). A wave of Eylea biosimilars is already on the market or clearing legal hurdles, eating into a franchise that once brought in about $6B a year. Could a giant copy it? No, they are blocked.
03
What protects it. Regeneron Genetics Center's 3 million linked exomes feed a proprietary drug pipeline that biosimilar makers cannot copy.
What would change this call
Eylea/Eylea HD quarterly revenue trend through 2026 earnings reports. Shows whether biosimilar erosion from Amgen, Sandoz, Celltrion, Biocon is accelerating.
Outcome of Fianlimab-Libtayo securities class action (lead plaintiff deadline Sept 14, 2026). Indicates financial and reputational cost of the failed Phase 3 melanoma trial.
Dupixent global net sales figures in 2026 quarterly reports. Shows whether growth offsets Eylea losses or the top line starts shrinking.
Outcome of Fianlimab-Libtayo securities class action (lead plaintiff deadline Sept 14, 2026). Indicates financial and reputational cost of the failed Phase 3 melanoma trial.
Dupixent global net sales figures in 2026 quarterly reports. Shows whether growth offsets Eylea losses or the top line starts shrinking.
Key numbers
- FY2025 revenue $14.3B, roughly flat YoY
- Dupixent Q2 2025 sales $4.34B, up ~21% YoY
- Cash and securities $17.5B vs $2.7B debt
Named risks
- Multi-front Eylea biosimilar erosion from Amgen, Sandoz, Celltrion and Biocon through end of 2026.
- Securities class-action litigation over Fianlimab trial failure, lead plaintiff deadline September 14 2026.
- MFN pricing deal and pharmaceutical tariff policy could compress near-term US revenue and margins.
- Pipeline setback risk if a second major trial fails after May 2026 Fianlimab failure.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Amgen (Pavblu) | gaining on | Eylea biosimilar live on market since November 2024 |
| Sandoz (Enzeevu) | gaining on | Cleared to launch Eylea biosimilar by Q4 2026 per settlement |
| Celltrion | gaining on | Settlement dated Oct 22 2025 permits Eylea biosimilar launch by end of 2026 |
| Biocon Biologics (Yesafili) | gaining on | Already commercializing Eylea biosimilar under 2025 settlement |
| Merck and Bristol Myers Squibb | contesting | Libtayo competes directly with Keytruda and Opdivo in checkpoint inhibitor oncology |
| Novo Nordisk and Eli Lilly | contesting | Regeneron positions trevogrumab as add-on to semaglutide, not head-on GLP-1 rival, per 2025 COURAGE trial data |
Questions people ask
- Is Regeneron profitable in 2026?
- Yes. Regeneron posted FY2025 net income of $4.50 billion on $14.3 billion revenue, and Q1 2026 revenue rose 19% year over year to $3.6 billion as of March 31, 2026. The company held $17.5 billion in cash as of June 30, 2025, giving it a strong financial cushion despite pipeline and pricing pressures.
- Is Eylea losing ground to biosimilars in 2026?
- Yes, actively. Amgen's Pavblu launched November 2024, Biocon's Yesafili is already commercializing, and Sandoz's Enzeevu and Celltrion's biosimilar are both cleared to launch by end of 2026 under settlements, creating a multi-front erosion of Regeneron's historically roughly $6 billion Eylea franchise.
- What happened with Regeneron's Fianlimab drug trial?
- The Phase 3 Fianlimab-Libtayo melanoma trial failed to reach statistical significance on progression-free survival, disclosed May 15, 2026. This triggered multiple securities class-action lawsuits alleging Regeneron misled investors, covering an August 1, 2025 to May 15, 2026 class period, with a lead plaintiff deadline of September 14, 2026.
- Could AI replace Regeneron's drug discovery work?
- Unlikely soon. Regeneron's Genetics Center holds roughly 3 million sequenced exomes linked to health records, an asset built over a decade that outside analysts call unreplicable by public-data AI tools. Its own chief data scientist said in May 2026 that useful AI target discovery needs tens of millions of records, far beyond current industry scale.
- Who is Regeneron's biggest competitor threat right now?
- The most acute threat is the wave of Eylea biosimilars: Amgen's Pavblu (live since November 2024), Biocon's Yesafili (already commercializing), and Sandoz and Celltrion both cleared to launch by end of 2026, directly eroding Regeneron's largest historical franchise.
- Why did Regeneron's stock drop in 2026?
- Regeneron shares fell from about $731 on April 28, 2026 toward the $629 to $676 range by July 20, 2026, market cap around $71 billion, after the May 15, 2026 Fianlimab Phase 3 failure triggered analyst price-target cuts from BofA, Morgan Stanley, Piper Sandler, and others.
Timeline
- 2026-07-20Shares trade near $676, down from 52-week high of $821.11, market cap ~$71B
- 2026-05-15Phase 3 Fianlimab-Libtayo melanoma trial fails to hit statistical significance
- 2026-04-29Q1 2026 results: revenue $3.6 billion, up 19% year over year
- 2026-04-23Signs MFN drug-pricing deal with Trump administration, cuts Praluent price from $537 to $225
- 2026-03-04Regeneron Genetics Center joins Alliance for Genomic Discovery, pooled dataset hits 312,000 whole genomes
- 2025-10-22Settles Eylea patent dispute with Celltrion, allowing biosimilar launch by end of 2026
- 2025-09-09Settlement lets Sandoz launch Eylea biosimilar Enzeevu by Q4 2026
- 2025-08-01Q2 2025 revenue reported at $3.68 billion, up 4% year over year
- 2024-11-01Amgen launches Pavblu, first major Eylea biosimilar on the US market
Revision history
20 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Regeneron Q2 2025 slides (2025-08-01)
- Regeneron Reports First Quarter 2026 Financial and Operating Results (2026-04-29)
- Regeneron Reports Second Quarter 2025 Financial and Operating Results (2025-08-01)
- Regeneron Q2 2025 Earnings Call Transcript (2026-02-05)
- Regeneron Pharmaceuticals (REGN) Number of Employees 1996-2025 (2026-07-08)
- Alliance for Genomic Discovery expands with Regeneron Genetics Center membership (2026-03-04)
- Levi & Korsinsky Urges Shareholders (2026-07-20)
- Regeneron Sued for Securities Law Violations (2026-07-20)
- Settlement allows Sandoz to launch Eylea biosimilar (2025-09-09)
- Trump touts Regeneron drug pricing deal (2026-04-23)
- gurufocus.com (2026-07-20)
- Semaglutide Combinations Show Promise (2025-06-03)